Autolus Therapeutics Change In Working Capital Over Time
| AUTL Stock | USD 3.32 0.05 1.53% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Autolus Therapeutics Performance and Autolus Therapeutics Correlation. Autolus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Working Capital Analysis
Compare Autolus Therapeutics and related stocks such as Cullinan Oncology LLC, Bolt Biotherapeutics, and Day One Biopharmaceu Change In Working Capital Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGEM | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 345 K | 135 K | 6.9 M | (3.5 M) | 11.2 M | (339 K) | (322.1 K) |
| BOLT | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 2.3 M | (2.3 M) | 20.5 M | (3.1 M) | (9.9 M) | (9.4 M) |
| DAWN | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | 444 K | (357 K) | 2.7 M | 6.6 M | 9.4 M | 9.9 M |
| LYRA | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 79 K | 2.1 M | (879 K) | 13.9 M | 4.6 M | (4.9 M) | (4.6 M) |
| ABOS | 768 K | 768 K | 768 K | 768 K | 768 K | 768 K | 768 K | 768 K | 768 K | 768 K | 307 K | 298 K | 4 M | 3.9 M | 2 M |
| XFOR | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | (517 K) | 3.4 M | (4.5 M) | (3.2 M) | (4.1 M) | (1.5 M) | 5.7 M | 344 K | 361.2 K |
| INZY | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 601 K | (111 K) | 85 K | 2 M | (3.1 M) | (2.9 M) |
| TERN | (352 K) | (352 K) | (352 K) | (352 K) | (352 K) | (352 K) | (352 K) | (352 K) | (352 K) | 1.8 M | 5.1 M | (1.4 M) | (1 M) | 1.3 M | 708.1 K |
| IKNA | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | (7.8 M) | (33 M) | (15.1 M) | (21.7 M) | (20.6 M) |
| ANEB | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | (1.4 M) | 907.8 K | 1.2 M | (799.3 K) | (759.3 K) |
| CELC | 167.9 K | 167.9 K | 167.9 K | 167.9 K | 167.9 K | 167.9 K | 161.8 K | (101.9 K) | 15.9 K | (62.2 K) | 179 K | 812.1 K | (1.3 M) | 3.9 M | 4.1 M |
| MNOV | 248 K | 2.3 M | (880.5 K) | (7.9 M) | 8.3 M | (393.8 K) | 302.9 K | (265.5 K) | (775.4 K) | (319.9 K) | (169.4 K) | (1.2 M) | 334.1 K | 112 K | 117.6 K |
| RZLT | (1.1 K) | (1.1 K) | 955.5 K | 488.4 K | 380.1 K | (119.2 K) | (155.4 K) | 1 M | 8.4 M | (7.5 M) | (2.1 M) | (642 K) | 1 M | 3.1 M | 3.3 M |
| APLS | 238.8 K | 238.8 K | 238.8 K | 238.8 K | 175 K | 628.3 K | 42.6 K | (1.2 M) | (12 M) | 53.1 M | 19.6 M | (93.5 M) | (15.7 M) | (200.2 M) | (190.2 M) |
Autolus Therapeutics and related stocks such as Cullinan Oncology LLC, Bolt Biotherapeutics, and Day One Biopharmaceu Change In Working Capital description
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.My Equities
My Current Equities and Potential Positions
| Autolus Therapeutics | AUTL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | United Kingdom |
| Exchange | NASDAQ Exchange |
USD 3.32
Check out Autolus Therapeutics Performance and Autolus Therapeutics Correlation. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Autolus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.